A novel antibody-drug conjugate:disitamab vedotin
10.12092/j.issn.1009-2501.2024.11.015
- VernacularTitle:新型抗体偶联药物——维迪西妥单抗
- Author:
Xiaoyu YIN
1
;
Ming LU
;
Zefang YU
;
Guoxun PANG
Author Information
1. 河北省人民医院药学部,石家庄 050051,河北;河北省临床药学重点实验室,石家庄 050051,河北
- Publication Type:Journal Article
- Keywords:
antibody-drug conjugates;
disitamab vedotin;
HER2
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(11):1315-1320
- CountryChina
- Language:Chinese
-
Abstract:
Antibody drug conjugates(ADCs)are a new class of anti-tumor drugs in which linkers in the structure link cytotoxic drugs to monoclonal an-tibodies and release cytotoxic drugs to tumors.Disi-tamab vedotin(RC48)is a new antibody-drug con-jugate independently developed in China.It targets the HER2 protein on the surface of tumors,it has both antibody targeting and small molecule drug killing,and can accurately recognize and kill tumor cells.Compared with traditional HER2-targeted drugs,disitamab vedotin has a wider therapeutic window and less toxicity to normal tissues.Current-ly,disitamab vedotin for injection has been ap-proved by the National Medical Products Adminis-tration(NMPA)for use in patients with HER2 over-expression(HER2 immunohistochemical results of 2+or 3+)who have locally advanced or metastatic gastric cancer(including gastroesophageal junction adenocarcinoma)and have received at least two types of systemic chemotherapy.Additionally,it is indicated for patients with locally advanced or met-astatic urothelial carcinoma who have previously undergone platinum-containing chemotherapy and exhibit HER2 overexpression,specifically 2+or 3+immunohistochemical results.In this paper,we will review the structural characteristics,mechanism of action and clinical trials of disitamab vedotin and look forward to the clinical application prospects of this drug.
